Latest News
Recent News
-
MEN2B and Family Planning Survey
In collaboration with clinicians at St Bartholomew’s Hospital in London, AMEND would like to learn more about attitudes and experiences of those affected by MEN2B (also known as MEN3) to family planning.
Click to learn more and to participate
-
New MEN1 App Launched
Today, AMEND has launched an app for MEN1 members ensuring that information is always at hand, even if offline. The app replaces the traditional, expensive, and slow-to-receive hardcopy MEN1 Member Pack.
Click here for more information
-
Grant from The Albert Hunt Trust
We are hugely grateful to the Trustees of The Albert Hunt Trust who have granted AMEND £5,000 towards 2026 core costs.
-
2026 Peer Support Meetings
We are pleased to confirm the dates for our 2026 Peer Support Meetings for those with MEN or PPGL syndromes. You can book now to connect with others.
Click here to view dates and to book
-
New Phase 3 Clinical Trial for Hyperinsulinism Drug
The upLIFT study, phase 3 clinical trial of ersodetug for tumour hyperinsulinism (HI), a drug from Rezolute (a late-stage rare disease company) is now enrolling participants through 2 UK centres.
Click to learn more
-
MEN2B Added to Generation Study
MEN2B RET mutation 918 to be added to the Genomics England’s Generation Study from March 2026.
Learn more